Aspirin and the risk of prostate cancer

Cristina Bosetti, Renato Talamini, Eva Negri, Silvia Franceschi, Maurizio Montella, Carlo La Vecchia

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% Cl) 0.81-1.50). No relation was found with duration of use (OR=1.03 for <5 years, and 1.17 for ≥ 5 years) and time since first use (OR=1.03 for <10 years, and 1.35 for ≥ 10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.

Original languageEnglish
Pages (from-to)43-45
Number of pages3
JournalEuropean Journal of Cancer Prevention
Volume15
Issue number1
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Aspirin
Prostatic Neoplasms
Odds Ratio
Italy
Case-Control Studies
Epidemiologic Studies
Prostate
Confidence Intervals
Carcinoma

Keywords

  • Aspirin
  • Case-control study
  • Prostate cancer
  • Risk factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aspirin and the risk of prostate cancer. / Bosetti, Cristina; Talamini, Renato; Negri, Eva; Franceschi, Silvia; Montella, Maurizio; La Vecchia, Carlo.

In: European Journal of Cancer Prevention, Vol. 15, No. 1, 02.2006, p. 43-45.

Research output: Contribution to journalArticle

Bosetti, Cristina ; Talamini, Renato ; Negri, Eva ; Franceschi, Silvia ; Montella, Maurizio ; La Vecchia, Carlo. / Aspirin and the risk of prostate cancer. In: European Journal of Cancer Prevention. 2006 ; Vol. 15, No. 1. pp. 43-45.
@article{1d52824de74f489fbe0b4b81b7cfb1ec,
title = "Aspirin and the risk of prostate cancer",
abstract = "Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1{\%}) cases versus 90 (8.0{\%}) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95{\%} confidence interval (95{\%} Cl) 0.81-1.50). No relation was found with duration of use (OR=1.03 for <5 years, and 1.17 for ≥ 5 years) and time since first use (OR=1.03 for <10 years, and 1.35 for ≥ 10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.",
keywords = "Aspirin, Case-control study, Prostate cancer, Risk factor",
author = "Cristina Bosetti and Renato Talamini and Eva Negri and Silvia Franceschi and Maurizio Montella and {La Vecchia}, Carlo",
year = "2006",
month = "2",
doi = "10.1097/01.cej.0000180665.04335.de",
language = "English",
volume = "15",
pages = "43--45",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Aspirin and the risk of prostate cancer

AU - Bosetti, Cristina

AU - Talamini, Renato

AU - Negri, Eva

AU - Franceschi, Silvia

AU - Montella, Maurizio

AU - La Vecchia, Carlo

PY - 2006/2

Y1 - 2006/2

N2 - Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% Cl) 0.81-1.50). No relation was found with duration of use (OR=1.03 for <5 years, and 1.17 for ≥ 5 years) and time since first use (OR=1.03 for <10 years, and 1.35 for ≥ 10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.

AB - Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% Cl) 0.81-1.50). No relation was found with duration of use (OR=1.03 for <5 years, and 1.17 for ≥ 5 years) and time since first use (OR=1.03 for <10 years, and 1.35 for ≥ 10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.

KW - Aspirin

KW - Case-control study

KW - Prostate cancer

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=30044439706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30044439706&partnerID=8YFLogxK

U2 - 10.1097/01.cej.0000180665.04335.de

DO - 10.1097/01.cej.0000180665.04335.de

M3 - Article

C2 - 16374228

AN - SCOPUS:30044439706

VL - 15

SP - 43

EP - 45

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - 1

ER -